Part 2: From Topicals to Biologics: Evolution of Treatment Options in Severe Alopecia Areata

In Part 2 of our expert-led discussion on alopecia areata (AA), dermatologists Dr Brittany Craiglow, Dr Brett King, and Dr Maryanne Senna dive into one of the most important breakthroughs in dermatology: the evolution of treatment options for severe AA, particularly the rise of JAK inhibitors as the new standard of care.

This segment explores how our deepening understanding of AA’s immunologic underpinnings has revolutionized care—from the limited success of traditional topicals and steroids to the game-changing efficacy of FDA-approved JAK inhibitors like baricitinib, ritlecitinib, and deuruxolitinib. The panel outlines clinical decision-making for initiating JAK therapy, managing real-world challenges like partial response or slow regrowth, and how to handle safety conversations—including boxed warnings and tapering protocols—with confidence and compassion.